FY2025 EPS Estimate for Beam Therapeutics Lifted by Analyst

Beam Therapeutics Inc. (NASDAQ:BEAM) – Stock analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for Beam Therapeutics in a report issued on Wednesday, March 12th. Cantor Fitzgerald analyst R. Bienkowski now anticipates that the company will post earnings of ($3.27) per share for the year, up from their prior forecast of ($3.55). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share.

BEAM has been the subject of several other research reports. Guggenheim reissued a “buy” rating and set a $78.00 price objective on shares of Beam Therapeutics in a research report on Thursday, February 27th. Wedbush reissued an “outperform” rating and set a $57.00 price objective on shares of Beam Therapeutics in a research report on Monday, March 10th. Sanford C. Bernstein raised Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 7th. Royal Bank of Canada boosted their price objective on Beam Therapeutics from $24.00 to $26.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 26th. Finally, Jones Trading upgraded Beam Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price target on the stock in a research note on Monday, March 10th. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Beam Therapeutics has an average rating of “Buy” and an average target price of $50.82.

Beam Therapeutics Stock Performance

NASDAQ BEAM opened at $24.23 on Friday. Beam Therapeutics has a twelve month low of $20.84 and a twelve month high of $36.75. The stock has a market capitalization of $2.42 billion, a PE ratio of -13.77 and a beta of 1.91. The stock has a 50-day simple moving average of $27.09 and a 200 day simple moving average of $26.01.

Beam Therapeutics (NASDAQ:BEAM) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.09) earnings per share for the quarter, topping the consensus estimate of ($1.25) by $0.16. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The business had revenue of $30.00 million during the quarter, compared to analysts’ expectations of $16.47 million. During the same quarter in the previous year, the firm earned $1.73 EPS. The firm’s revenue was down 90.5% compared to the same quarter last year.

Insider Activity

In related news, insider Christine Bellon sold 1,241 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total transaction of $30,627.88. Following the sale, the insider now directly owns 102,968 shares in the company, valued at $2,541,250.24. This represents a 1.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John M. Evans sold 30,000 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $26.75, for a total value of $802,500.00. Following the sale, the chief executive officer now owns 908,659 shares in the company, valued at approximately $24,306,628.25. This trade represents a 3.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Beam Therapeutics

A number of large investors have recently bought and sold shares of the business. Horizon Kinetics Asset Management LLC grew its position in Beam Therapeutics by 4.4% during the 4th quarter. Horizon Kinetics Asset Management LLC now owns 9,597 shares of the company’s stock worth $238,000 after acquiring an additional 403 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in Beam Therapeutics by 6.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,999 shares of the company’s stock worth $198,000 after buying an additional 496 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Beam Therapeutics by 2.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,396 shares of the company’s stock worth $524,000 after buying an additional 516 shares in the last quarter. Martingale Asset Management L P lifted its holdings in Beam Therapeutics by 8.6% during the 4th quarter. Martingale Asset Management L P now owns 11,438 shares of the company’s stock worth $284,000 after buying an additional 909 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in Beam Therapeutics by 0.8% during the 4th quarter. Swiss National Bank now owns 137,800 shares of the company’s stock worth $3,417,000 after buying an additional 1,100 shares in the last quarter. 99.68% of the stock is currently owned by institutional investors.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.